Please login to the form below
Orfadin
This page shows the latest Orfadin news and features for those working in and with pharma, biotech and healthcare.
Orphan drug firm Sobi opens new European base
In July the European Commission approved an oral suspension formulation of Orfadin (nitisinone), which treats the rare - and potentially fatal - genetic disease Hereditary Tyrosinaemia type-1 (HT-1). ... More recently the FDA this week began its review
Latest news
-
Sobi wins European approval for oral form of orphan drug Orfadin
Expandstreatment options for rare genetic disease HT-1. . The European Commission has approved an oral suspension formulation of Swedish Orphan Biovitrum's (Sobi) Orfadin (nitisinone). ... An oral suspension of Orfadin for paediatric use will
-
PatientsLikeMe takes aim at one of world's rarest diseases
disease. Although there is currently no cure for AKU, Swedish Orphan Biovitrum's tyrosinaemia treatment Orfadin (nitisinone) is used off-label to treat AKU and is expected to enter phase III
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Director
-
Competitive Salary Offered
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Associate Director
-
£75, 000-90, 000
-
Account Director, Medical Education
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Global Business Development Director – Health Education
-
excellent commission
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Medical Writer
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
-
Senior Account Manager
-
Competitive Salary Offered
Subscribe to our email news alerts
- Pfizer takeover rumour ignites Amarin shares
- Welcome to the Communique Awards - Communiqué Awards 2018
- NICE rejects Novartis migraine treatment Aimovig
- GSK upbeat on its return to oncology market
- AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
- AZ’s Sean Bohen to exit after business overhaul; report
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
- Escaping the spin cycle of sub-optimal launch
- ...
Quick links
Infographics
